Evidence map›Paper›PMID 35581257›Full record

ArticleNature communications2022

Author Correction: Tumour gene expression signature in primary melanoma predicts long-term outcomes.

Manik Garg, Dominique-Laurent Couturier, Jérémie Nsengimana, Nuno A Fonseca, Matthew Wongchenko, Yibing Yan, Martin Lauss, Göran B Jönsson, Julia Newton-Bishop, Christine Parkinson and 16 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors.

Manik GargEuropean Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Hinxton, Cambridgeshire, UK.ORCID http://orcid.org/0000-0003-0453-2058
Dominique-Laurent CouturierCancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, UK.ORCID http://orcid.org/0000-0001-5774-5036
Jérémie NsengimanaUniversity of Leeds School of Medicine, Leeds, United Kingdom.ORCID http://orcid.org/0000-0002-3603-4208
Nuno A FonsecaCIBIO/InBIO-Centro de Investigação em Biodiversidade e Recursos Genéticos, Universidade do Porto, Rua Padre Armando Quintas, 4485-601, Vairão, Portugal.ORCID http://orcid.org/0000-0003-4832-578X
Matthew WongchenkoOncology Biomarker Development, Genentech Inc., 1 DNA Way, South San Francisco, CA, 94080, USA.ORCID http://orcid.org/0000-0003-1230-7117
Yibing YanOncology Biomarker Development, Genentech Inc., 1 DNA Way, South San Francisco, CA, 94080, USA.
Martin LaussLund University Cancer Center, Lund University, Lund, Sweden.
Göran B JönssonLund University Cancer Center, Lund University, Lund, Sweden.
Julia Newton-BishopUniversity of Leeds School of Medicine, Leeds, United Kingdom.
Christine ParkinsonCambridge Cancer Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Mark R MiddletonOxford NIHR Biomedical Research Centre and Department of Oncology, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0003-0167-1685
D Timothy BishopUniversity of Leeds School of Medicine, Leeds, United Kingdom.ORCID http://orcid.org/0000-0002-8752-8785
Sarah McDonaldDepartment of Pathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Nikki StefanosDepartment of Pathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
John TadrossDepartment of Pathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.ORCID http://orcid.org/0000-0002-8424-1252
Ismael A VergaraMelanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia.ORCID http://orcid.org/0000-0002-2960-2967
Serigne LoMelanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia.ORCID http://orcid.org/0000-0001-5092-5544
Felicity NewellQIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.ORCID http://orcid.org/0000-0003-0469-2705
James S WilmottMelanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia.
John F ThompsonMelanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia.ORCID http://orcid.org/0000-0002-2816-2496
Georgina V LongMelanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia.
Richard A ScolyerMelanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia.ORCID http://orcid.org/0000-0002-8991-0013
Pippa CorrieCambridge Cancer Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
David J Adams *Experimental Cancer Genetics, The Wellcome Sanger Institute, Hinxton, Cambridgeshire, UK.ORCID http://orcid.org/0000-0001-9490-0306
Alvis Brazma *European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Hinxton, Cambridgeshire, UK.ORCID http://orcid.org/0000-0001-5988-7409
Roy Rabbie *Cambridge Cancer Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. rr13@sanger.ac.uk.ORCID http://orcid.org/0000-0002-9195-5659

Funding

Cancer Research UK 11963Cancer Research UK 19167Medical Research Council MR/M019012/1Medical Research Council MR/V000292/1
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID35581257
PMCPMC9114317

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.